Investment will allow the Cambridge-based biotech company to transform women’s health through innovative tissue-level therapeutics.
Cyclana Bio’s initial focus is on endometriosis, a chronic condition affecting 1 in 10 women globally, where the underlying causes are not yet fully understood and treatment options remain limited.
The investment will support in advancing the company’s platform and developing functional disease models that use tissue-level therapeutics to target endometriosis.
Cyclana Bio’s research focuses on the extracellular matrix (ECM), the structure surrounding cells that helps them communicate. Dysregulation of the ECM, such as when it’s damaged or behaves abnormally, can cause inflammation and tissue problems – both key issues in endometriosis. By combining donated menstrual fluid with lab-based modelling, and integrating multi-scale data and AI, they’re able to detect early indicators of disease and pinpoint promising targets for drug development.
This pioneering methodology not only holds promise for endometriosis but also offers a platform to address other chronic inflammatory diseases with similar tissue-level mechanisms.
Edward Sloan, head of venture capital investments in Mills & Reeve’s London office, commented: “We are proud to support Cyclana Bio in its journey to bring forward a new generation of therapeutics.”
Dr Léa Wenger, CEO and founder at Cyclana Bio, added: "Ed and his team provided amazing support and guidance and were instrumental to closing in the smoothest way possible. They struck a good balance on the negotiations and were, in general, a pleasure to work with."
The investment was co-led by NfX and Eka VC, with participation from Cocoa VC, Wilbe, and a group of angel investors.
Our content explained
Every piece of content we create is correct on the date it’s published but please don’t rely on it as legal advice. If you’d like to speak to us about your own legal requirements, please contact one of our expert lawyers.